# OnCo record nct03436485 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03436485/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03436485", "NCT03436485" ;
  schema:name "Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer"@en ;
  schema:alternateName "CYPIDES"@en ;
  schema:description "A phase 1/2 trial of Opevesostat in prostate cancer, run by Orion Corporation, Orion Pharma, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03436485/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03436485> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2018-03-19" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/> ;
  onco:drugs <https://onco.cc/drugs/opevesostat/> ;
  onco:companies <https://onco.cc/companies/orion-orion-pharma/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct03436485-nejm-evid-2024/> .